Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Dow
Covington
Queensland Health
Cerilliant
Fish and Richardson
McKesson
Mallinckrodt
Federal Trade Commission
Colorcon

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,449,464

« Back to Dashboard

Summary for Patent: 7,449,464
Title:Phthalazinone derivatives
Abstract: Compounds of the formula (I): ##STR00001## wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NR.sup.X or CR.sup.XR.sup.Y; if X=NR.sup.X then n is 1 or 2 and if X=CR.sup.XR.sup.Y then n is 1; R.sup.X is selected from the group consisting of H, optionally substituted C.sub.1-20 alkyl, C.sub.5-20 aryl, C.sub.3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; R.sup.Y is selected from H, hydroxy, amino; or R.sup.X and R.sup.Y may together form a spiro-C.sub.3-7 cycloalkyl or heterocyclyl group; R.sup.C1 and R.sup.C2 are both hydrogen, or when X is CR.sup.XR.sup.Y, R.sup.C1, R.sup.C2, R.sup.X and R.sup.Y, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R.sup.1 is selected from H and halo.
Inventor(s): Martin; Niall Morrison Barr (Cambridge, GB), Smith; Graeme Cameron (Cambridge, GB), Jackson; Stephen Philip (Cambridge, GB), Loh; Vincent Junior M (Horsham, GB), Cockcroft; Xiao-Ling Fan (Horsham, GB), Matthews; Ian Timothy Williams (Horsham, GB), Menear; Keith Allan (Horsham, GB), Kerrigan; Frank (Cornwall, GB), Ashworth; Alan (London, GB)
Assignee: Kudos Pharmaceuticals Limited (Cambridge, GB) Maybridge Limited (Cornwall, GB)
Application Number:10/876,080
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,449,464

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca Pharms LYNPARZA olaparib CAPSULE;ORAL 206162-001 Dec 19, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-001 Aug 17, 2017 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-002 Aug 17, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,449,464

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0305681.9Mar 12, 2003

Non-Orange Book US Patents Family Members for Patent 7,449,464

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,662,818 Phthalazinone derivatives ➤ Subscribe
9,566,276 Phthalazinone derivatives ➤ Subscribe
8,912,187 Phthalazinone derivatives ➤ Subscribe
9,169,235 Phthalazinone derivatives ➤ Subscribe
7,981,889 Phthalazinone derivatives ➤ Subscribe
8,071,579 DNA damage repair inhibitors for the treatment of cancer ➤ Subscribe
8,143,241 DNA damage repair inhibitors for treatment of cancer ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,449,464

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 102107008 ➤ Subscribe
Colombia 5650256 ➤ Subscribe
Cyprus 1111597 ➤ Subscribe
Germany 602004032537 ➤ Subscribe
Denmark 1633724 ➤ Subscribe
Denmark 1684736 ➤ Subscribe
Denmark 2305221 ➤ Subscribe
Eurasian Patent Organization 200501434 ➤ Subscribe
Eurasian Patent Organization 009469 ➤ Subscribe
Ecuador SP056094 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Novartis
Healthtrust
Baxter
Farmers Insurance
McKinsey
US Department of Justice
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot